Cancers | |
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells | |
Roberto Gomez-Casal3  Chitralekha Bhattacharya3  Michael W. Epperly3  Per H. Basse3  Hong Wang3  Xinhui Wang2  David A. Proia1  Joel S. Greenberger3  Mark A. Socinski3  Vera Levina3  | |
[1] Synta Pharmaceuticals Corp., 45 Hartwell Avenue, Lexington, MA 02421, USA; E-Mail:;Harvard Medical School, Harvard University, 25 Shattuck Street, Boston, MA 02115, USA; E-Mail:;The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; E-Mails: | |
关键词: HSP90 inhibitor ganetespib; lung adenocarcinoma; xenografted tumors; ionizing radiation; senescence; apoptosis; cell cycle; DNA repair; | |
DOI : 10.3390/cancers7020814 | |
来源: mdpi | |
【 摘 要 】
The molecular chaperone HSP90 is involved in stabilization and function of multiple client proteins, many of which represent important oncogenic drivers in NSCLC. Utilization of HSP90 inhibitors as radiosensitizing agents is a promising approach. The antitumor activity of ganetespib, HSP90 inhibitor, was evaluated in human lung adenocarcinoma (AC) cells for its ability to potentiate the effects of IR treatment in both
【 授权许可】
CC BY
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190012083ZK.pdf | 2351KB | download |